Kura Oncology 2016 Tipifarnib FTase Inhibitor Presentation

Kura Oncology presents Tipifarnib, a farnesyl transferase inhibitor being developed for HRAS-mutant cancers, with Phase 2 data from ASCO 2017. The company, led by CEO Troy Wilson, has 24 employees and operates with approximately $50M in cash and a burn rate of $7M quarterly, projecting runway through end-2018.